Epidermal growth factor receptor content in rat prostatic adenocarcinoma: effects of endocrine treatment.
Epidermal growth factor receptor (EGF-R) was studied in Dunning prostatic cancer models using competitive binding assays and solution hybridization assay. EGF-R-binding capacity and mRNA were demonstrated in a hormone-sensitive R3327 prostatic tumor from both control and castrated animals while no such activity was found in the hormone-independent AT-1 tumors. Castration induced no quantitative changes in the EGF-R. Estrogen treatment induced a significant reduction of the binding capacity of EGF-R and its mRNA. It was concluded that EGF-R is present in the androgen-sensitive Dunning prostatic tumor models (R3327), but that the androgen-insensitive, undifferentiated AT-1 tumor lacks EGF-R expression. Endocrine treatment has no significant effect on the EGF-R in these tumor models.
Damber
J E
JE
Department of Urology and Andrology, University of Umeå, Sweden.
Bergh
A
A
Assarsson
B
B
Gåfvels
M
M
D000230:Adenocarcinoma / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy*; D000728:Androgens / Q000502:physiology; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D004967:Estrogens / Q000627:therapeutic use*; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
D000728:Androgens; D004967:Estrogens; D012333:RNA, Messenger; D066246:ErbB Receptors